In this article, we will take a detailed look at 10 stocks with at least $10 million in insider sales recently. We previously covered 10 stocks with at least $30 million in insider spending recently.
Some of the major U.S. indexes began recovering on Wednesday, following the Trump administration’s announcement of a one-month delay on tariffs for automakers meeting the United States-Mexico-Canada Agreement (USMCA) requirements. The news sparked enthusiasm among traders, who began hoping for additional exemptions, causing the major stock indexes to rise slightly.
Blue-chip companies gained 485.60 points or 1.14%, the broader market index rose 1.12%, while the NASDAQ stocks increased 1.46%. These rebounds come during a volatile week following a period of consecutive declines.
Although many analysts have lowered their U.S. stock forecasts, citing that strong earnings in 2025 may be more challenging to achieve, the broader market index is still projected to end the year about 9% higher than in 2024. However, this is lower than the initial forecast of 12.2%, made in early January.
On the other hand, the big bets for this year are a productivity boost from the adoption of AI and the projection of lower interest rates. Dan Ives, global head of technology research at Wedbush Securities, said that while tariffs are never good for Wall Street, investors should take advantage of these periods to invest in the best tech stocks, reports CNN Business.
Amid market fluctuations and uncertainty, insider trading often attracts significant attention. Executives and insiders, with their in-depth knowledge of company strategies, plans, and future prospects, may make trades worth analyzing. For instance, when a CEO or CFO invests their own funds in company stock, it can serve as a strong indicator of confidence in the company’s future potential.
Selling shares, on the other hand, may suggest that management is losing confidence, though this is not always the case. In some instances, large shareholders may simply be rebalancing their portfolios to better align with their desired risk/reward profile or selling for personal financial reasons. Additionally, many insiders sell shares as part of pre-arranged, automated trading plans known as 10b5-1 plans.
Both insider buying and selling can be influenced by various factors, so these actions should be interpreted within the broader context of the company’s financial health, industry trends, and overall market conditions. This highlights the importance of conducting thorough research before making investment decisions. While insider trading activity can offer valuable insights into a company’s prospects, it should be considered alongside other critical factors to ensure well-informed investment choices.
A close up of a financial trader typing on a laptop at a market trading desk.
Today, we’re focusing on stocks that have seen insider sales of at least $10 million since the start of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least one insider sale reached $10 million or more. While the total value of insider sales for these stocks may be higher, we focused on sales worth $10 million or more. Out of the stocks that met this criterion, we selected the 10 stocks with insider sales ranging from $10 million to $20 million, prioritizing those with the highest insider sales within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million year-to-date, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider sales since the beginning of the year.
10. AbbVie Inc. (NYSE:ABBV)
Highest Individual Sale: $18,964,470.60
Number of Sales Above $10 million: 1
Market Capitalization: $373.44 billion
AbbVie is a biopharmaceutical company engaged in the development of advanced therapies across various healthcare sectors. The North Chicago, Illinois-headquartered company offers a broad range of treatments in immunology, oncology, neurology, and eye care. It also markets well-known cosmetic products such as Juvederm and Botox for skincare and anti-aging.
On February 28, one insider sold $18.96 million worth of AbbVie shares at a price of $205.11 per share. AbbVie shares jumped that day on the news that The European Medicines Agency’s CHMP has recommended approving upadacitinib for treating adults with giant cell arteritis (GCA). The final decision from the European Commission is expected by mid-2025. If approved, upadacitinib would be the first oral advanced therapy for adults with GCA.
Currently, the stock is trading at $211.54 per share, having risen 19.04% since the beginning of the year. Over the past 12 months, AbbVie returned 16.83% to its investors.
In March, AbbVie and Gubra A/S (CPSE:GUBRA), announced a licensing agreement to develop GUB014295, a potential long-acting amylin analog for obesity treatment. GUB014295, currently in Phase 1 trials, is designed to activate amylin and calcitonin receptors, with amylin identified as a key target for obesity treatment. AbbVie views this partnership as an opportunity to enter the obesity field and drive long-term growth.
Twenty-one analysts have given an average “Strong Buy” rating to AbbVie stock, with a price target of $212.7, according to Stock Analysis.
AbbVie is also one of the 10 most undervalued long term stocks to buy now.
9. Amkor Technology, Inc. (NASDAQ:AMKR)
Highest Individual Sale: $18,999,995.25
Number of Sales Above $10 million: 2
Market Capitalization: $5.11 billion
Ninth stock among the 10 with at least $10 million in insider sales this year, is a provider of outsourced semiconductor packaging and testing services across the U.S., Japan, Europe, and the Asia Pacific region, Amkor Technology. The Tempe, Arizona-based company provides turnkey packaging and testing services, such as semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, system-level and final testing, and more. It is also one of the 10 stocks with at least $10 million in insider spending recently.
On February 24, one insider made two sales each valued at nearly $19 million. J James Kim, who is a large shareholder at Amkor sold a total of 1.74 million shares at a price of $21.85 per share. Currently, the stock is trading at $20.72 per share, having lost 19.35% year-to-date.
In February, the company’s board of directors declared a quarterly cash dividend of $0.08269 per share on the company’s common stock.
For the full year of 2024, Amkor disclosed net sales of $6.32 billion, down from $6.50 billion in 2023. Net income attributable to Amkor was $354 million, or $1.43 per diluted share, compared to $360 million, or $1.46 per diluted share, in 2023.
Ten analysts have an average “Moderate Buy” rating on Amkor stock, with a price target of $31.50, according to MarketBeat. The average price target represents an upside of 52.03% from the current price.
